Rol' razlichnykh vidov renin-angiotenzinovoy sistemy v patogeneze serdechno-sosudistykh zabolevaniy. Fokus na valsartan


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

This review summarizes the clinical and experimental data on the complex nature of the renin-angiotensin-aldosterone system (RAAS), including the classic endocrine RAAS, tissue renin-angiotensin system (RAS) located on the cell surface, and intracellular RAS. The mechanisms of intracrine activation of cells of cardiovascular system, underlying cardiac hypertrophy, remodeling, fibrosis, and formation of cardiac insufficiency, are discussed. The results of the action of valsartan - fat-soluble ATi receptor antagonist are analyzed, including its impact on the three types of RAS, as well as the consequences of its actions on the ATi receptors of different locations.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Astashkin

Email: 287ast@mail.ru

M. Glezer

Әдебиет тізімі

  1. ESH/ESC Guidelines for the management of arterial hypertension J. Hypertens. 2013;31:1281-357.
  2. Асташкин Е.И., Глезер М.Г. Ренин-ангиотензиновая система - новые звенья в старой цепи. М., 2010. 20 с.
  3. Асташкин Е.И. Глезер М.Г. Новые данные о функционировании ренин-ангиотензиновой системы: роль внутриклеточной (итракринной) системы. Проблемы женского здоровья. 2012;7(4):47-54.
  4. Re R.N. Lysosomal action of intracrine angiotensin II. Focus on "Intracellular angiotensin II activates rat myometrium. Am. J. Physiol. Cell Physiol. 2011;301(3):553-54.
  5. Abadir P.M., Foster D.B., Crow M., et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl. Acad. Sci. 2011;108(36):1484-54.
  6. Tadevosyan A., Maguy A, Villeneuve L.R., et al. Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J. Biol. Chem. 2010;285(29):22338-49.
  7. Kumar R., Yong Q.C., Thomas C.M., Baker K.M. Intracardiac intracellular angiotensin system in diabetes. Am. J. Physiol. Reg. Integ. Comp. Physiol. 2012;302(5):R510-17.
  8. Асташкин Е.И. Глезер М.Г. Жирорастворимые ингибиторы АПФ - особенности влияния на РАС. М., 2012. 12 с.
  9. Hu D., Liu L., Li W. Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 chinese patients with hypertension: an observational study. Adv Ther. 2014;31(7):762-75.
  10. Sison J., Assaad-Khalil S.H., Najem R., et al. Real-world clinical experience of amlodipine/ valsartan and amlodipine/valsartan/ hydrochlorothiazide in hypertension: the EXCITE study. Curr. Med. Res. Opin. 2014;17:1-9.
  11. Maggioni A.P., Fabbri G. VALIANT(VALsartan In Acute myocardial iNfarcTion) trial. Expert Opin. Pharmacother. 2005;6(3):507-12.
  12. Cohn J.N., Tognoni G. Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001;345(23):1667-75.
  13. Beers D.M. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198-205.
  14. Kurokawa J, Abriel H. Neurohormonal regulation of cardiac ion channels in chronic heart failure. J. Cardiovasc. Pharmacol. 2009;54(2): 98-105.
  15. Benitah J.P, Alvarez J.L., Gomez A.M. L-type Ca(2+) current in ventricular cardiomyocytes. J. Mol. Cell Cardiol. 2010;48(1):26-36.
  16. Yano M., Ikeda Y., Matsuzaki M. Altered intracellular Ca2+ handling in heart failure. J. Clin. Investigation. 2005;115(3):556-64.
  17. Luo M., Anderson M.E. Mechanism of altered Ca2+ handling in heart failure Circ. Res. 2013;113(6):690-708.
  18. Hasenfuss G., Pieske B. Calcium cycling in congestive heart failure. J. Mol. Cell Cardiol. 2002;34(8):951-69.
  19. Dedkova E.N., Blatter L.A. Mitochondrial Ca2+ and the heart. Cell Calcium. 2008;44(1):77-91.
  20. Hobai I.A., O'Rourke B. Decreased sarcoplasmic reticulum calcium content is responsiblefor defective excitation-contraction couplingin canine heart failure. Circulation. 2001;103(11):1577-84.
  21. Lou Q, Fedorov V.V., Glukhov A.V., Transmural heterogeneity and remodeling of ventricular excitation-contraction coupling in human heart failure. Circulation. 2011;123(17):1881-90.
  22. Liu T., Takimoto E., Dimaano V.L., et al. Inhibiting mitochondrial Na+/Ca2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ. Res. 2014;115(1):44-54.
  23. Rokita A.G., Anderson M.E. New therapeutic targets in cardiology: arrhythmias and Ca2+/ calmodulin-dependent kinase II (CaMKII). Circulation. 2012;126(17):2125-39.
  24. Yang X., Jun H. Effect of valsartan and fosinopril on cathecholamine-induced catdiac hypertrophy. Acta Pharmacol. Sin. 2000;21(9):850-54.
  25. Liu T., Brown D.A., O'Rourke B. Role of mitochondrial dysfunction in cardiac glycoside toxicity. J. Mol. Cell Cardiol. 2010;49(5):728-36.
  26. Lu J.X., Zhu J.H., Qin X.T., et al. Role of valsartan on myocardial Calpain I, calceunern and Ca/calmodulin-dependent protein kinase II-d expression of renovascular hypertensive rats. Zhonghua xin guan bing za zhi. 2012;40(6):511-15.
  27. Qu F.Z., Lio Z.H., Jiang B., et al. Valsartan improved cardiac function in heart failure rabbits probably via down regulations myocardial CaMKII expression and activity. Zhonghua xin guan bing za zhi. 2009;37(6):501-05.
  28. Асташкин Е.И. Глезер М.Г. Роль L-карнитина в энергетическом обмене кардиомиоцитов и лечении заболеваний сердечно-сосудистой системы Кардиология и сердечно-сосудистая хирургия. 2012;6(2):58-65.
  29. Nakamae H., Tsumura K., Terada Y., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104(11):2492-98.
  30. Xu Li, Zhang Ying, Wang Jian, et al., Effect of valsartan on rats' heart mitochondria of adriamycin-induced cardiomyopathy. J. Jiangsu University (Medicine Edition). 2010-01.
  31. Monteiro P., Duarte A.I., Gonzalves L.M., Providencia L.A. Valsartan improves mitochondrial function in hearts submitted to acute ischemia. Eur. J. Pharmacol. 2005;518(2-3): 158-64.
  32. Rizos C.V., Elisaf M.S. Antihypertensive drugs and glucose metabolism. World J. Cardiol. 2014;6(7):517-30.
  33. Глезер М.Г. Антигипертензивная терапия и развитие новых случаев сахарного диабета. Можно ли снизить риск? Кардиоваскулярная терапия и профилактика. 2008;7(8): 85-93.
  34. Iwashita M., Sakoda H., Kushiyama A., et al. Valsartan, independently of AT1 receptor or PPAR-gamma suppresses LPS-indused macrophage activation and improves insulin resistance in cocultured adipocytes. Am. J. Physiol. Endocrinol. Metab. 2012;302(3): E286-96.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>